You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for New Drug Application (NDA): 215152


✉ Email this page to a colleague

« Back to Dashboard


NDA 215152 describes VOQUEZNA TRIPLE PAK, which is a drug marketed by Phathom and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the VOQUEZNA TRIPLE PAK profile page.

The generic ingredient in VOQUEZNA TRIPLE PAK is amoxicillin; clarithromycin; vonoprazan fumarate. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; clarithromycin; vonoprazan fumarate profile page.
Summary for 215152
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 215152
Generic Entry Date for 215152*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW
Dosage:
CAPSULE, TABLET, TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 215152
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VOQUEZNA TRIPLE PAK amoxicillin; clarithromycin; vonoprazan fumarate CAPSULE, TABLET, TABLET;ORAL 215152 NDA Phathom Pharmaceuticals Inc. 81520-255 81520-255-14 14 BLISTER PACK in 1 CARTON (81520-255-14) / 1 KIT in 1 BLISTER PACK (81520-255-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, TABLET, TABLET;ORALStrength500MG;500MG;EQ 20MG BASE
Approval Date:May 3, 2022TE:RLD:Yes
Regulatory Exclusivity Expiration:May 3, 2032
Regulatory Exclusivity Use:GENERATING ANTIBIOTIC INCENTIVES NOW
Regulatory Exclusivity Expiration:May 3, 2027
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:⤷  Sign UpPatent Expiration:Aug 11, 2028Product Flag?Substance Flag?YDelist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.